Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2008 June;56(3) > Minerva Cardioangiologica 2008 June;56(3):335-48

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  PEDIATRIC HEART FAILURE 

Minerva Cardioangiologica 2008 June;56(3):335-48

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

Stem cells in pediatric heart failure

Pillekamp F. 1, Khalil M. 2, Emmel M. 1, Brockmeier K. 1, Hescheler J. 2

1 Department of Pediatric Cardiology, University of Cologne, Cologne, Germany 2 Institute of Neurophysiology, University of Cologne, Cologne, Germany


PDF


Pediatric heart failure could be a target for regenerative therapy. Stem cell-based therapy has the potential to provide functional cardiomyocytes. Whereas adult stem cells have shown no or only minimal therapeutic benefit in adults with no evidence of transdifferentiation, embryonic stem cells can differentiate to any cell type, including cardiomyocytes. However, ethical concerns and immunological problems are associated with embryonic stem cells derived from the inner cell mass of blastocysts. Recently, somatic cells could be reprogrammed to a pluripotent state (i.e. induced pluripotent stem cells) with the help of transcription factors. This technique removes ethical and probably also immunological concerns. Nevertheless extensive experimental research will be necessary before cell replacement strategies become clinically applicable. Because the underlying pathophysiology differs significantly with age, caution is warranted extrapolating data obtained in experimental models of cardiac ischemia and clinical studies in adults to the pediatric population. Pediatric heart failure has a good prognosis if causal therapy is possible. However, some forms of congenital heart disease and especially dilated cardiomyopathy still have limited therapeutic options. Almost half of children with symptomatic cardiomyopathy receive a transplant or die within two years. The authors will review the relevant stem cell sources for cell-based treatments. And, given the differences of the underlying diseases between adult and pediatric patients with heart failure, it is contemplated which condition of pediatric patients with heart failure is most likely to benefit and which cell type would be appropriate.

top of page